Sonar to Improve the Quality of AI-Generated Code, Provide Automated Fix Recommendations
3.10.2024 16:00:00 EEST | Business Wire | Press release
Sonar, the leading Clean Code solution provider, today announced two new product capabilities for today’s AI-driven software development ecosystem. These new capabilities are designed to support better software development in two critical and distinct ways – Sonar AI Code Assurance and Sonar AI CodeFix improve the quality of code produced by generative AI and enhance Sonar’s offering with AI to deliver a better developer experience, respectively. Both capabilities deepen Sonar’s commitment to the delivery of high-quality, secure code and increasing developer productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003439224/en/
Sonar introduces AI Code Assurance and AI CodeFix to improve the quality of code produced by generative AI. (Photo: Business Wire)
AI Code Assurance helps organizations ensure the quality of AI-generated code by thoroughly analyzing the codebase for issues, ensuring that projects using AI tools to generate code meet high standards of quality and security. Today, bad code is already estimated to cost businesses more than a trillion dollars, making it critical for AI-generated code, which promises to increase the volume of code written, to be comprehensively checked for quality and security issues.
“AI is transforming the way developers work, streamlining processes, and reducing the toil associated with writing code. As the adoption of AI coding assistants grows, however, we are seeing a new issue emerge: code accountability. AI-generated code needs review by developers, but accountability for doing this is increasingly diluted. As a result, we’re seeing the review step frequently being shortchanged,” said Tariq Shaukat, CEO of Sonar. “With AI Code Assurance, we’re helping organizations ensure that AI written code receives the high level of quality and security review that you would expect from your developers.”
AI CodeFix allows developers to seamlessly resolve issues detected by Sonar's code analysis engine with a single click, directly within their workflow. The AI-powered fix recommendations help streamline developer workflows, speed up issue remediation, and improve the developer experience. As leading research has established, developer experience improves with the automation that AI provides. For example, McKinsey reported that developers using generative AI tools in their work stream are “twice as likely to report overall happiness, fulfillment, and a state of flow” than those who aren’t.
“AI CodeFix helps developers streamline their workflow and ramp up their productivity. Rather than switching between solutions or manual efforts, we’re putting remediation options for Sonar-identified issues right in front of the people working on them – and giving them the ability to fix the issues in an instant. We’re excited to see how our users adopt this capability and better understand how we can further integrate AI into our solutions to improve the developer experience,” said Fabrice Bellingard, VP of Product at Sonar.
The features are currently available for both SonarQube and SonarCloud.
AI Code Assurance for Confidence in Code Quality
With AI Code Assurance for SonarQube and SonarCloud, developers can be confident that their AI-generated code is clean and secure. By implementing the Sonar AI Code Assurance workflow, organizations have the assurance that all code (AI-generated and human-developed) has been thoroughly scanned for issues and that projects leveraging AI tools are meeting high standards of quality and security.
AI Code Assurance capabilities include:
- Project Tagging: Developers can easily tag projects that contain AI-generated code, initiating a comprehensive analysis through the Sonar AI Code Assurance workflow.
- Quality Gate Enforcement: An optimized quality gate for AI-generated code ensures that only code meeting strict quality and security standards is approved for production.
- AI Code Assurance Approved Badge: Projects that pass the quality gate receive a badge signifying that the code has gone through a rigorous AI-ready analysis.
AI CodeFix for Fast Issue Remediation
Fast-paced software development environments require solutions that enhance productivity, reduce time-to-market, and maintain high code quality. Today, millions of Sonar users can detect and fix issues in their code leveraging Sonar’s database of code rules and best practices. Now, at the click of a button, developers can use AI CodeFix to automatically generate solutions to issues in the same SonarQube and SonarCloud user interface where they review issues.
AI CodeFix capabilities include:
- Instant Code Fixes: Minimize manual debugging efforts and increase productivity by automatically generating code fix suggestions.
- Contextual Understanding of Sonar findings: Leverages LLMs to understand code context and provide relevant fixes.
- Seamless Integration: Developers fix issues directly within their IDE using SonarLint connected mode, ensuring a smooth workflow.
- Continuous Learning: Ongoing suggestion improvements based on user feedback
- Multi-Language Support: Supports flagship programming languages such as Java, JS/TS, C#, Python, and C/C++.
AI Code Assurance is now available on SonarQube and will be generally available in SonarCloud by the end of October. AI CodeFix is available for early access in SonarQube Enterprise Edition, SonarQube Data Center Edition, and SonarCloud Team and Enterprise plans.
For more information on the new features, visit our AI features page at https://www.sonarsource.com/solutions/ai/.
About Sonar
Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003439224/en/
Contacts
Media
Katie Hyman
Senior PR Manager for Sonar
(707) 291-1469
press@sonarsource.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom